ATYR — aTyr Pharma Share Price
0.000.00%
Last trade - 00:00- $319.89m
- $249.01m
- $0.24m
- 15
- 4
- 100
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.57 | ||
| Price to Tang. Book | 4.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,361.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.96% | ||
| Return on Equity | -79.69% | ||
| Operating Margin | -28899.57% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.46 | n/a | 10.39 | 0.35 | 0.23 | 1.5 | 33.67 | -11.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
Directors
- John Clarke NEC (67)
- Sanjay Shukla PRE (49)
- Jill Broadfoot CFO (59)
- Nancy Denyes GCN (53)
- Sara Zaknoen DRC (56)
- Timothy Coughlin IND (54)
- Jane Gross IND (64)
- Svetlana Lucas IND (49)
- Paul Schimmel IND (80)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 8th, 2005
- Public Since
- May 7th, 2015
- No. of Shareholders
- 30
- No. of Employees
- 56
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 88,858,612
- Address
- 10240 Sorrento Valley Road, Suite 300, SAN DIEGO, 92121
- Web
- https://www.atyrpharma.com/
- Phone
- +1 8587318389
- Auditors
- Ernst & Young LLP
Upcoming Events for ATYR
Q2 2025 aTyr Pharma Inc Earnings Release
Similar to ATYR
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the aTyr Pharma share price?
As of Today at 19:25 UTC, shares in aTyr Pharma are trading at $3.60. This share price information is delayed by 15 minutes.
How has the aTyr Pharma share price performed this year?
Shares in aTyr Pharma last closed at $3.60 and the price had moved by +125% over the past 365 days. In terms of relative price strength the aTyr Pharma share price has outperformed the S&P500 Index by +102.89% over the past year.
What are the analyst and broker recommendations for aTyr Pharma?
The overall consensus recommendation for aTyr Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the aTyr Pharma dividend yield?
aTyr Pharma does not currently pay a dividend.
Does aTyr Pharma pay a dividend?
aTyr Pharma does not currently pay a dividend.
When does aTyr Pharma next pay dividends?
aTyr Pharma does not currently pay a dividend.
How do I buy aTyr Pharma shares?
To buy shares in aTyr Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of aTyr Pharma?
As of the previous close price of $3.60, shares in aTyr Pharma had a market capitalisation of $319.89m.
Where are aTyr Pharma shares listed?
Here are the trading details for aTyr Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATYR
What kind of share is aTyr Pharma?
Based on an overall assessment of its quality, value and momentum aTyr Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a aTyr Pharma share price forecast for 2025?
The analyst consensus target price for shares in aTyr Pharma is $18.83. That is 423.06% above the last closing price of $3.60.
Analysts covering aTyr Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.70 for the next financial year.
Find out moreWhat is the trend in the aTyr Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like aTyr Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +18.96%.
As of the last closing price of $3.60, shares in aTyr Pharma were trading +23.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the aTyr Pharma PE Ratio?
The aTyr Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of aTyr Pharma?
aTyr Pharma's management team is headed by:
- John Clarke - NEC
- Sanjay Shukla - PRE
- Jill Broadfoot - CFO
- Nancy Denyes - GCN
- Sara Zaknoen - DRC
- Timothy Coughlin - IND
- Jane Gross - IND
- Svetlana Lucas - IND
- Paul Schimmel - IND